TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
BACKGROUND In this retrospective study we evaluated effectiveness and safety of bortezomib, comparingour results with already published clinical studies. METHODS Patients received bortezomib as part of everyday clinical practice and in the range ofapproved indications. We evaluated bortezomib effect...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2008-04-01
|
| Series: | Zdravniški Vestnik |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/877 |
| _version_ | 1818128338037768192 |
|---|---|
| author | Veronika Kodre Peter Černelč |
| author_facet | Veronika Kodre Peter Černelč |
| author_sort | Veronika Kodre |
| collection | DOAJ |
| description | BACKGROUND
In this retrospective study we evaluated effectiveness and safety of bortezomib, comparingour results with already published clinical studies.
METHODS
Patients received bortezomib as part of everyday clinical practice and in the range ofapproved indications. We evaluated bortezomib effectiveness in 66 patients according tomodified SWOG criteria and treatment responsiveness (CR, VGPR, PR, MR) or unresponsiveness (SD, PD). Treatment responsiveness was compared according to high risk (beta-2microglobulin ? 5,5 mg/L) or standard risk (beta-2 mikroglobulin < 5.5 mg/L), patient’sage (> 65 ali < 65 let), number of previous treatments (1 ali > 1) and previous treatmentwith thalidomid. Side effects and reasons for early treatment discontinuation were alsoevaluated.
RESULTS
Patients received 1–7 previous treatments (median 1.5). Treatment responsiveness wasobserved in 80.3 % patients (1.5 % CR, 45.5 % VGPR, 21.2 % PR and 12.1 % MR). Nostatistical significant influence was observed according to: high risk (p = 0.178), age above65 years (p = 0.756), > 1 previous treatment (p = 0.419) or previous treatment with thalidomid (p = 0.475). Side effects of bortezomib treatment were: anemia (40.9 %), peripheralneuropathy grade 3 or more (28.7 %), infections (21.2 %), herpes zooster (12.1 %), neutropenia (10.6 %), trombocitopenia (9 %) and gastro-intestinal problems (7.5 %). Earlydiscontinuation was observed due to: peripheral neuropathy (28.7 %), other seriousside effects (6 %), bortezomib uneffectiveness (19.7 %) or planned autologous transplant(15.1 %).
CONCLUSIONS
Bortezomib (Velcade) is effective and safe treatment also for patients with multiple myeloma that developed resistance to previous treatments or belong to high risk patient group |
| first_indexed | 2024-12-11T07:31:39Z |
| format | Article |
| id | doaj.art-bb2cef741509404da3e76600380a6fa7 |
| institution | Directory Open Access Journal |
| issn | 1318-0347 1581-0224 |
| language | English |
| last_indexed | 2024-12-11T07:31:39Z |
| publishDate | 2008-04-01 |
| publisher | Slovenian Medical Association |
| record_format | Article |
| series | Zdravniški Vestnik |
| spelling | doaj.art-bb2cef741509404da3e76600380a6fa72022-12-22T01:15:49ZengSlovenian Medical AssociationZdravniški Vestnik1318-03471581-02242008-04-0177SUPPI755TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIBVeronika KodrePeter ČernelčBACKGROUND In this retrospective study we evaluated effectiveness and safety of bortezomib, comparingour results with already published clinical studies. METHODS Patients received bortezomib as part of everyday clinical practice and in the range ofapproved indications. We evaluated bortezomib effectiveness in 66 patients according tomodified SWOG criteria and treatment responsiveness (CR, VGPR, PR, MR) or unresponsiveness (SD, PD). Treatment responsiveness was compared according to high risk (beta-2microglobulin ? 5,5 mg/L) or standard risk (beta-2 mikroglobulin < 5.5 mg/L), patient’sage (> 65 ali < 65 let), number of previous treatments (1 ali > 1) and previous treatmentwith thalidomid. Side effects and reasons for early treatment discontinuation were alsoevaluated. RESULTS Patients received 1–7 previous treatments (median 1.5). Treatment responsiveness wasobserved in 80.3 % patients (1.5 % CR, 45.5 % VGPR, 21.2 % PR and 12.1 % MR). Nostatistical significant influence was observed according to: high risk (p = 0.178), age above65 years (p = 0.756), > 1 previous treatment (p = 0.419) or previous treatment with thalidomid (p = 0.475). Side effects of bortezomib treatment were: anemia (40.9 %), peripheralneuropathy grade 3 or more (28.7 %), infections (21.2 %), herpes zooster (12.1 %), neutropenia (10.6 %), trombocitopenia (9 %) and gastro-intestinal problems (7.5 %). Earlydiscontinuation was observed due to: peripheral neuropathy (28.7 %), other seriousside effects (6 %), bortezomib uneffectiveness (19.7 %) or planned autologous transplant(15.1 %). CONCLUSIONS Bortezomib (Velcade) is effective and safe treatment also for patients with multiple myeloma that developed resistance to previous treatments or belong to high risk patient grouphttp://vestnik.szd.si/index.php/ZdravVest/article/view/877 |
| spellingShingle | Veronika Kodre Peter Černelč TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB Zdravniški Vestnik |
| title | TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB |
| title_full | TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB |
| title_fullStr | TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB |
| title_full_unstemmed | TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB |
| title_short | TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB |
| title_sort | treatment of multiple myeloma with bortezomib |
| url | http://vestnik.szd.si/index.php/ZdravVest/article/view/877 |
| work_keys_str_mv | AT veronikakodre treatmentofmultiplemyelomawithbortezomib AT petercernelc treatmentofmultiplemyelomawithbortezomib |